TAB 008Alternative Names: TAB008; TOT102
Latest Information Update: 18 Nov 2016
At a glance
- Originator TOT Biopharm
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 11 Nov 2016 Phase-I clinical trials in Non-small cell lung cancer (In volunteers) in China (IV) (ChiCTR-IIR-16009827)